DNA SCRIPT SAS

Their core work

DNA Script is a French technology SME specialising in enzymatic DNA synthesis — using engineered enzymes rather than traditional chemical methods to write DNA strands. Their core commercial work focused on scaling this synthesis technology toward industrial production, and they have since extended into DNA-based data storage, where synthesised DNA is used as an ultra-dense, long-lived digital storage medium. In practice they sit at the intersection of biotechnology, instrumentation, and emerging data infrastructure.

What they specialise in

How they've shifted over time

In Rosalind (2018-2020) the work was industrialising enzymatic DNA synthesis — a biochemistry and process-engineering problem. By DNA-FAIRYLIGHTS (2021-2025) they had applied that synthesis capability to DNA-based data storage, bringing in new competencies around plasmonics, nanopores and optical readout. The shift is from "writing DNA at scale" to "using written DNA as a storage medium".

They are positioning their DNA-writing platform as the foundation for DNA data storage, meaning future collaborations around archival storage, nanopore sequencing and optical detection are a natural fit.

How they like to work

DNA Script has taken both lead and partner roles — coordinating a EUR 2.5M SME scale-up project and then joining a smaller research consortium as a contributor. The pattern suggests a company comfortable running its own commercial-facing projects while also plugging into academic research when the science aligns with its platform. They are a relatively concentrated collaborator, with only eight unique partners across five countries.

A modest but focused European network — 8 unique partners across 5 countries, anchored in France but reaching into other EU research hubs through both SME and fundamental-research instruments.

What sets them apart

Very few European SMEs own a proprietary enzymatic DNA synthesis platform, and even fewer are actively applying it to DNA data storage. This dual identity — biotech process company plus emerging deep-tech data infrastructure player — is what sets DNA Script apart from both traditional oligo suppliers and pure-research storage labs. For a partner, they bring actual synthesis capability, not just know-how.

Highlights from their portfolio

• Rosalind
  Largest project by far (EUR 2.5M) and the one they coordinated — a commercial scale-up of enzymatic DNA synthesis under the SME instrument.
• DNA-FAIRYLIGHTS
  Marks their entry into DNA data storage, combining their synthesis expertise with plasmonics and nanopore-based optical readout.